Tags : Nanobody-based Medicines


Sanofi Collaborates with i2O Therapeutics to Evaluate Oral i2O Therapeutics

Shots: The companies collaborated to investigate oral delivery of Sanofi’s Nanobody based medicines, which are currently available in IV & SC formulations The collaboration will advance the formulation of therapies that are traditionally limited to injections. Nanobodies are the therapeutic proteins based on camelid-derived immunoglobulin single variable domains & have potential to treat multiple diseases […]Read More